DeBehnke D J, Spreng D, Wickman L L, Crowe D T
Department of Emergency Medicine, Medical College of Wisconsin, Milwaukee 53226, USA.
Acad Emerg Med. 1996 Feb;3(2):137-41. doi: 10.1111/j.1553-2712.1996.tb03401.x.
To study the hemodynamic effects of exogenously administered endothelin-1 (ET-1), a peptide produced by endothelial cells with potent non-adrenergically mediated vasoconstrictor properties.
A prospective drug intervention study was carried out in a resuscitation research laboratory. Fifteen mixed-breed dogs were anesthetized and instrumented for hemodynamic monitoring. Asphyxia arrest was produced by clamping the endotracheal tube. Hemodynamic data were collected continuously. Following loss of aortic fluctuations monitored by thoracic aortic catheter, the animals remained in pulseless electrical activity (PEA) for 10 minutes. After 10 minutes of no-flow PEA, closed-chest CPR was begun and the animals were randomized to one of three treatment groups (EPI, 0.02 mg/kg epinephrine IV every 3 minutes; ENDO, 100 micrograms ET-1 IV at 0 minutes; and EPI/ENDO, a combination of the EPI and ENDO treatments).
ENDO and EPI alone produced similar coronary perfusion pressures (CPPs). The EPI/ENDO combination produced significantly improved CPP compared with that of either EPI or ENDO alone. In the EPI group, the best mean CPP was 16 +/- 14 mm Hg and occurred 7 minutes after drug administration. In the ENDO group, the best mean CPP was 28 +/- 7 mm Hg and occurred 13 minutes after drug administration. In the EPI/ENDO combination group, the best mean CPP was 61 +/- 37 mm Hg and occurred 7 minutes after drug administration (p < 0.05 compared with the EPI and ENDO groups alone).
ET-1 is a potent vasoconstrictor. The combination of EPI and ENDO significantly improved CPP compared with that for either agent alone. ET-1 should be investigated further as a vasoconstrictor in cardiac arrest.
研究外源性给予内皮素-1(ET-1)的血流动力学效应,ET-1是一种由内皮细胞产生的具有强大非肾上腺素能介导血管收缩特性的肽。
在复苏研究实验室进行一项前瞻性药物干预研究。15只杂种犬麻醉后安装血流动力学监测仪器。通过夹闭气管导管造成窒息性心脏停搏。持续收集血流动力学数据。在经胸主动脉导管监测到主动脉波动消失后,动物处于无脉电活动(PEA)状态10分钟。无血流PEA持续10分钟后,开始进行闭胸心肺复苏(CPR),并将动物随机分为三个治疗组之一(EPI组,每3分钟静脉注射0.02mg/kg肾上腺素;ENDO组,在0分钟静脉注射100μg ET-1;EPI/ENDO组,EPI和ENDO治疗联合应用)。
单独使用ENDO和EPI产生相似的冠状动脉灌注压(CPP)。与单独使用EPI或ENDO相比,EPI/ENDO联合应用显著提高了CPP。在EPI组,最佳平均CPP为16±14mmHg,在给药后7分钟出现。在ENDO组,最佳平均CPP为28±7mmHg,在给药后13分钟出现。在EPI/ENDO联合应用组,最佳平均CPP为61±37mmHg,在给药后7分钟出现(与单独的EPI组和ENDO组相比,p<0.05)。
ET-1是一种强效血管收缩剂。与单独使用任何一种药物相比,EPI和ENDO联合应用显著提高了CPP。ET-1作为心脏骤停时的血管收缩剂应进一步研究。